JP2025516596A - 多重特異性結合分子プロタンパク質及びその使用 - Google Patents

多重特異性結合分子プロタンパク質及びその使用 Download PDF

Info

Publication number
JP2025516596A
JP2025516596A JP2024566352A JP2024566352A JP2025516596A JP 2025516596 A JP2025516596 A JP 2025516596A JP 2024566352 A JP2024566352 A JP 2024566352A JP 2024566352 A JP2024566352 A JP 2024566352A JP 2025516596 A JP2025516596 A JP 2025516596A
Authority
JP
Japan
Prior art keywords
abs
domain
binding molecule
mbm
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516596A5 (OSRAM
Inventor
ヘイバー、ローリック
クロフォード、アリソン
チャン、トン
スミス、エリック
リン、チャ－ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2025516596A publication Critical patent/JP2025516596A/ja
Publication of JP2025516596A5 publication Critical patent/JP2025516596A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024566352A 2022-05-11 2023-05-10 多重特異性結合分子プロタンパク質及びその使用 Pending JP2025516596A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263340891P 2022-05-11 2022-05-11
US63/340,891 2022-05-11
US202363481291P 2023-01-24 2023-01-24
US63/481,291 2023-01-24
US202363489812P 2023-03-13 2023-03-13
US63/489,812 2023-03-13
PCT/US2023/066841 WO2023220647A1 (en) 2022-05-11 2023-05-10 Multispecific binding molecule proproteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2025516596A true JP2025516596A (ja) 2025-05-30
JP2025516596A5 JP2025516596A5 (OSRAM) 2026-05-18

Family

ID=86760424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566352A Pending JP2025516596A (ja) 2022-05-11 2023-05-10 多重特異性結合分子プロタンパク質及びその使用

Country Status (9)

Country Link
US (1) US20250340668A1 (OSRAM)
EP (1) EP4522649A1 (OSRAM)
JP (1) JP2025516596A (OSRAM)
KR (1) KR20250024872A (OSRAM)
CN (1) CN119546628A (OSRAM)
AU (1) AU2023269792A1 (OSRAM)
CA (1) CA3252786A1 (OSRAM)
IL (1) IL316892A (OSRAM)
WO (1) WO2023220647A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4735043A1 (en) * 2023-06-30 2026-05-06 The Regents of the University of California Pro-polypeptides and methods of using and designing the same
US20250297006A1 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2102007T3 (es) 1992-01-23 1997-07-16 Merck Patent Gmbh Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
HUE026278T2 (en) 2003-07-01 2016-05-30 Ucb Biopharma Sprl Modified Fab antibody fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2611834B1 (en) 2010-09-01 2018-03-07 Biogen MA Inc. Rapid generation of anti-idiotypic antibodies
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
AU2016333517B2 (en) 2015-10-02 2023-09-07 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
ES3034233T3 (en) 2016-01-22 2025-08-14 MabQuest SA Non-blocking pd1 specific antibodies
MA43724B1 (fr) 2016-03-22 2023-06-28 Hoffmann La Roche Molécules bispécifiques de cellules t activées par une protéase
US11390676B2 (en) 2016-10-13 2022-07-19 Symphogen A/S Anti-LAG-3 antibodies and compositions

Also Published As

Publication number Publication date
CN119546628A (zh) 2025-02-28
CA3252786A1 (en) 2023-11-16
US20250340668A1 (en) 2025-11-06
EP4522649A1 (en) 2025-03-19
AU2023269792A1 (en) 2024-11-28
WO2023220647A1 (en) 2023-11-16
IL316892A (en) 2025-01-01
KR20250024872A (ko) 2025-02-19

Similar Documents

Publication Publication Date Title
KR20240035845A (ko) Il12 수용체 효능제 및 그의 사용 방법
US20240067691A1 (en) Interferon receptor agonists and uses thereof
US20250340668A1 (en) Multispecific binding molecule proproteins and uses thereof
JP2025529805A (ja) インターフェロンプロタンパク質及びその使用
JP2025520175A (ja) インターロイキン－２プロタンパク質及びその使用
JP2025519158A (ja) インターロイキン－２プロタンパク質及びその使用
HK40116914A (zh) 多特异性结合分子前蛋白及其用途
US20250361309A1 (en) Tumor-targeted split il12 receptor agonists
HK40121930A (zh) 白细胞介素-2蛋白质原及其用途
HK40123893A (zh) 白细胞介素-2蛋白质原及其用途
HK40126891A (zh) 干扰素前蛋白及其用途
WO2025199243A1 (en) Trivalent multispecific binding molecules and methods of use thereof
HK40126890A (zh) 干扰素受体激动剂及其用途
KR20250166361A (ko) Mhc 도메인 및 항원 펩티드를 포함하는 펩티드-mhc 착물 및 면역 세포 항원 표적화 모이어티를 포함하는 다중특이적 분자
WO2026076013A1 (en) Tumor-targeted il2 receptor agonists and multispecific t-cell engagers
JP2026504072A (ja) Ｉｌ１２受容体アゴニストおよびその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260508